Skip to content

Role of Homoeopathic medicine in Rheumatoid arthritis

Comparative Effectiveness of Individualized Homoeopathic Medicine and Actea spicata in patients with Rheumatoid arthritis: An open label Randomised Controlled Clinical Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097299
Enrollment
32
Registered
2025-11-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M069- Rheumatoid arthritis, unspecified

Interventions

Intervention1: Individualised Homoeopathic medicine: After case taking Individualised Homoeopathic medicine will be prescribed to one arm based on Random number chart. Dose potency and repetition wil

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cases fulfilling the diagnostic criteria of rheumatoid arthritis ICD 10 M06.9 according to ACR or EULAR score more than 6 Cases with Anti CCP value above 20 IU per ml. Patients in the age group of 18-65 years Patients of all Sexes Religions and socio-economic condition. Patients who have not taken any treatment in the last 4 weeks for Rheumatoid Arthritis . Patients who are willing to give written informed consent.

Exclusion criteria

Exclusion criteria: Patients who are diagnosed with life threatening diseases uncontrolled systemic illness immune- compromised states psychiatric illness and malignancy Patients on NSAIDs or DMARDs. Pregnant women and lactating mothers. Patients with severe abuse and or dependence on any substance.

Design outcomes

Primary

MeasureTime frame
The response of the Rheumatoid arthritis patients for the IH treatment and Actea spicata will be evaluated by changes in DAS28 SCORE.Timepoint: At baseline, 3 months and 6 months

Secondary

MeasureTime frame
The response of the Rheumatoid arthritis patients for the IH treatment and Actea spicata will be evaluated by changes in Anti-CCP Levels.Timepoint: Baseline 3 month and 6 month

Countries

India

Contacts

Public ContactProf Dr Prasanta Rath

National Institute of Homoeopathy Kolkata

drprasantarath09@gmail.com8420924836

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026